insights_auto
Kāpēc uzņēmuma 4142 akciju cena ir samazinājusies 6,62%?
Atklājiet vairāk iespējuchevron_right
4142:TPE
Adimmune Corp
14,80 NT$
arrow_downward
-6,62%(-1,05) 1 d.
20. nov., 13:30:09 GMT+8 · TWD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: 4142…
Atvērt
15,75 NT$
Augsta
15,75 NT$
Zema
14,80 NT$
Tirgus kapitalizācija
6,36 mljrd.
Vid. apjoms
1,13 milj.
Apjoms
1,63 milj.
Cenas/peļņas attiecība
85,76
Augstākā 52 ned.
21,50 NT$
Zemākā 52 ned.
14,80 NT$
Peļņa uz vienu akciju
0,17 NT$
Apgrozībā esošās akcijas
235,29 milj.
Darbinieku skaits
564
Atvērt
15,75 NT$
Augsta
15,75 NT$
Zema
14,80 NT$
Tirgus kapitalizācija
6,36 mljrd.
Vid. apjoms
1,13 milj.
Apjoms
1,63 milj.
Cenas/peļņas attiecība
85,76
Augstākā 52 ned.
21,50 NT$
Zemākā 52 ned.
14,80 NT$
Peļņa uz vienu akciju
0,17 NT$
Apgrozībā esošās akcijas
235,29 milj.
Darbinieku skaits
564
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Adam Feldman | Substack
·
pirms 18 stundām
Inside the Federal Litigation of Five S&P 500 Giants
Yahoo Finance
·
pirms 2 stundām
SPDR S&P 500 ETF (SPY) Sells Apple and Microsoft on Nov. 18
MarketWatch
·
pirms 45 minūtēm
Stock Market Today: Dow, S&P 500 and Nasdaq set for flat-to-lower start in worst week for main index since Trump tariff announcement; Anthropic, AMD, Nvidia in focus: live updates
The Motley Fool
·
pirms 3 stundām
Bitcoin Is 35% Below Its 52-Week High While the S&P 500 Is Up. Here’s What That Says About the Digital Gold Thesis.
Profils
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Par “Adimmune Corp”
Ģenerāldirektors-
Darbinieki564
Dibināšanas datums1965
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietneadimmune.com.tw